{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:46:54Z","timestamp":1793936814068,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40265-020-01410-z","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T06:03:12Z","timestamp":1602482592000},"page":"1853-1858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Risdiplam: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"issue":"15","key":"1410_CR1","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 ( SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317.","journal-title":"J Med Chem"},{"issue":"6","key":"1410_CR2","doi-asserted-by":"publisher","first-page":"e00447","DOI":"10.1002\/prp2.447","volume":"6","author":"A Poirier","year":"2018","unstructured":"Poirier A, Weetall M, Heinig K, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018;6(6):e00447.","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"1410_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy: new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313.","journal-title":"J Neuromuscul Dis"},{"issue":"20","key":"1410_CR4","doi-asserted-by":"publisher","first-page":"E4604","DOI":"10.1073\/pnas.1800260115","volume":"115","author":"J Wang","year":"2018","unstructured":"Wang J, Schultz PG, Johnson KA. Mechanistic studies of a small-molecule modulator of SMN2 splicing. Proc Natl Acad Sci USA. 2018;115(20):E4604\u2013E46124612.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1410_CR5","unstructured":"Food and Drug Administration (FDA). FDA approves oral treatment for spinal muscular atrophy [media release]. 7 Aug 2020. https:\/\/www.fda.gov\/news-events\/."},{"key":"1410_CR6","unstructured":"Genentech Inc. Evrysdi\u2122 (risdiplam): US prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213535s000lbl.pdf. Accessed 24 Aug 2020."},{"key":"1410_CR7","unstructured":"SMA Foundation. SMA Foundation announces collaboration with PTC Therapeutics [media release]. 7 June 2006. https:\/\/smafoundation.org\/sma-press."},{"key":"1410_CR8","unstructured":"Roche. Roche signs agreement with PTC Therapeutics to advance treatment for spinal muscular atrophy (SMA) [media release]. 29 Nov 2011. https:\/\/www.roche.com."},{"key":"1410_CR9","unstructured":"PTC Therapeutics. PTC Therapeutics announces achievement of major milestone in SMA collaboration [media release]. 8 Aug 2013. https:\/\/ir.ptcbio.com."},{"key":"1410_CR10","unstructured":"PTC Therapeutics. Joint program in spinal muscular atrophy enters first stage of clinical development [media release]. 22 Jan 2014. https:\/\/ir.ptcbio.com."},{"key":"1410_CR11","unstructured":"PTC Therapeutics. PTC therapeutics announces FDA grants priority review to risdiplam for the treatment of spinal muscular atrophy [media release]. 25 Nov 2019. https:\/\/ir.ptcbio.com."},{"key":"1410_CR12","unstructured":"PTC Therapeutics. PTC announces the acceptance of the European Marketing Authorization application for Evrysdi\u2122 (risdiplam) for the treatment of spinal muscular atrophy [media release]. 17 Aug 2020. https:\/\/ir.ptcbio.com."},{"key":"1410_CR13","unstructured":"PTC Therapeutics. PTC Therapeutics announces first commercial milestone payment following US FDA approval of Evrysdi\u2122 (risdiplam) [media release]. 26 Aug 2020. https:\/\/ir.ptcbio.com."},{"key":"1410_CR14","doi-asserted-by":"crossref","unstructured":"Baranello G, Bertini E, Chiriboga C, et al. Pooled safety data from the risdiplam (RG7916) clinical trial development program [abstract no. 1267 plus oral presentation]. Neurology. 2020;94(15 Suppl).","DOI":"10.1212\/WNL.94.15_supplement.1267"},{"key":"1410_CR15","doi-asserted-by":"crossref","unstructured":"Sturm S, Gunther A, Jaber B, et al. A Phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2018;10.","DOI":"10.1111\/bcp.13786"},{"issue":"Suppl 1","key":"1410_CR16","first-page":"6","volume":"62","author":"G Baranello","year":"2020","unstructured":"Baranello G, Servais L, Day JW, et al. FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with Type 1 spinal muscular atrophy (SMA). Dev Med Child Neurol. 2020;62(Suppl 1):6.","journal-title":"Dev Med Child Neurol"},{"key":"1410_CR17","doi-asserted-by":"crossref","unstructured":"Servais L, Baranello G, Masson R, et al. FIREFISH Part 2: efficacy and safety of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA) [abstract no. 1302 plus oral presentation]. Neurology. 2020;94(15 Suppl).","DOI":"10.1183\/13993003.congress-2020.1172"},{"issue":"Suppl 1","key":"1410_CR18","first-page":"310","volume":"26","author":"D Vlodavets","year":"2019","unstructured":"Vlodavets D, Servais L, Baranello G, et al. FIREFISH Part 1: survival, ventilation and swallowing ability in infants with type 1 spinal muscular atrophy (SMA) treated with risdiplam (RG7916). Eur J Neurol. 2019;26(Suppl 1):310\u20131.","journal-title":"Eur J Neurol"},{"issue":"9","key":"1410_CR19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology"},{"key":"1410_CR20","doi-asserted-by":"crossref","unstructured":"Mercuri E, Barisic N, Boespflug-Tanguy O, et al. SUNFISH Part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) [abstract no. 1260 plus oral presentation]. Neurology. 2020;94(15 Suppl).","DOI":"10.1212\/WNL.94.15_supplement.1260"},{"key":"1410_CR21","unstructured":"PTC Therapeutics. PTC Therapeutics announces 2-year data from Part 1 of SUNFISH and new data from JEWELFISH trials for risdiplam in patients with spinal muscular atrophy [media release]. 12 Jun 2020. https:\/\/ir.ptcbio.com."},{"key":"1410_CR22","doi-asserted-by":"crossref","unstructured":"Chiriboga C, Bruno C, Day JW, et al. JEWELFISH: safety and pharmacodynamic data in non-na\u00efve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam (RG7916) [abstract no. 772 plus oral presentation]. Neurology. 2020;94(15 Suppl).","DOI":"10.1016\/j.nmd.2019.06.525"},{"key":"1410_CR23","doi-asserted-by":"crossref","unstructured":"Bertini E, Day J, Muhaizea M, et al. RAINBOWFISH: a study of risdiplam (RG7916) in newborns with pre-symptomatic spinal muscular atrophy (SMA) [abstract no. P.362]. Neuromuscul Disord. 2019;29 (Suppl 1):S187.","DOI":"10.1016\/j.nmd.2019.06.524"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01410-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01410-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01410-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T16:26:30Z","timestamp":1723739190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01410-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01410-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"12 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate and consent for publication, Availability of data and material, Code availability"}}]}}